Intronic Enhancer Activity of the Eosinophil-derived Neurotoxin (RNS2) and Eosinophil Cationic Protein (RNS3) Genes Is Mediated by an NFAT-1 Consensus Binding Sequence*

(Received for publication, May 10, 1996, and in revised form, October 24, 1996)

Jeffrey S. Handen and Helene F. Rosenberg Dagger

From the Laboratory of Host Defenses, NIAID, National Institutes of Health, Bethesda, Maryland 20892

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES


ABSTRACT

The eosinophil-derived neurotoxin (EDN) and eosinophil cationic protein (ECP) are both small, cationic ribonuclease toxins that are stored in and secreted by activated human eosinophilic leukocytes. We have previously shown that optimal expression of the EDN gene is dependent on an interaction between an intronic enhancer element or elements and the 5' promoter region. Here we present evidence demonstrating that the gene encoding ECP is regulated in an analogous fashion and that an intronic enhancer element functioning in both genes is a consensus binding sequence for the transcription factor NFAT-1. Our initial results demonstrate that one or more nuclear proteins isolated from human promyelocytic leukemia (HL-60) cells bind specifically at this consensus site (5'-GGAGAA-3') within the intron of the EDN gene and that disruption of this sequence reduced the characteristic 20-30-fold increase in reporter gene activity observed with the tandem EDN promoter/exon 1/intron construct to background levels. The NFAT-1 consensus site in the ECP gene differs from that found in the EDN gene by a single nucleotide (5'-GGAGAG-3'); the conversion of the 3' G to an A resulted in a further enhancement of the reporter gene activity supported by the ECP promoter/exon 1/intron construct. Interestingly, no "supershift" was observed in gel shift assays performed in the presence of anti-NFAT-1 antiserum, suggesting that a nuclear protein other than NFAT-1 may be acting at this consensus site.


INTRODUCTION

Eosinophil-derived neurotoxin (EDN1/RNS2) and eosinophil cationic protein (ECP/RNS3) are members of the mammalian ribonuclease (RNase A) superfamily and are two of four proteins found in the large specific granules of human eosinophilic leukocytes (1, 2). The genes encoding EDN and ECP are 90% homologous to one another and both include two exons; each gene contains a noncoding exon 1, separated by a single intron from the coding sequence in exon 2. This gene structure is characteristic of the ribonuclease gene family (3-6). In our previous work, we have demonstrated that optimal expression of the EDN gene is dependent on interaction between the 5' promoter region and the single intron (7). Further analysis of the EDN gene demonstrated that a significant portion of this intron-mediated enhancer activity resided within the first 60 base pairs of the intron, which includes consensus binding sites for both AP-1 and NFAT-1 transcription factors (7).

The NFAT-1 sequence is a consensus binding site for nuclear factor of activated T cells, preexisting (formerly known as NF-ATp), which was originally described as a cyclosporin-sensitive T lymphocyte-specific transcription factor (8-11) involved in the regulation of gene expression of several cytokine genes, including murine interleukin-2 (8), interleukin-3 (12), interleukin-4 (13-16), interleukin-5 (17), gp39 (18), granulocyte-macrophage colony-stimulating factor (19, 20), and tumor necrosis factor alpha  (21). NFAT-1 exists as a cytosolic protein that is dephosphorylated and translocated to the nucleus following T lymphocyte activation by a calcium/calcineurin dependent mechanism, where it interacts cooperatively with Fos-Jun dimers (11, 22, 23) to regulate gene expression. NFAT-1 is also involved in the regulation of expression of cytokine genes in B lymphocytes (24-26) and in mast cells (27) and of granulocyte-macrophage colony-stimulating factor in endothelial cells (12). NFAT-1 immunoreactivity has been observed in murine neuronal cell lines (28), suggesting an even wider role for this factor as a regulator of gene expression.

Here, we find that optimal expression of the ECP gene also depends on the presence of an intronic enhancer element, and we present evidence demonstrating a role for an NFAT-1 consensus sequence and its binding protein in the regulated expression of both EDN and ECP.


EXPERIMENTAL PROCEDURES

Cell Culture

All cell lines used in this investigation were obtained from the American Type Culture Collection (Rockville, MD). The HL-60 (human promyelocytic leukemia) and K-562 (human chronic myelogenous leukemia) cell lines were cultured in RPMI 1640 (Biofluids, Inc., Rockville, MD) supplemented with 10% heat-inactivated fetal bovine serum (Hyclone Laboratories, Inc., Gaithersburg, MD), 2 mM L-glutamine (Quality Biologicals, Inc., Gaithersburg, MD), and 100 units/ml penicillin plus 100 µg/ml streptomycin (Quality Biologicals). The HL-60 clone 15 promyelocytic leukemia cells were grown in RPMI 1640 with fetal bovine serum, L-glutamine, penicillin/streptomycin supplemented with 25 mM HEPPSO (N-[2-hydroxyethyl]piperazine-N'-[2-hydroxy-propanesulfonic acid] (Sigma), and maintained at pH 7.6. All cells were grown at 37 °C with 5% carbon dioxide in a humidified incubator.

Reporter Gene Constructs

The reporter gene used in these studies was chloramphenicol acetyltransferase (CAT) as found in the pCAT-basic plasmid vector (Promega, Madison, WI). Preparation of the EDN reporter gene constructs were as described previously (7); the construct EDN3-CAT described here is identical to that described as EDN-PrExInCAT in the aforementioned publication. The ECP reporter gene constructs (see Fig. 2B) were prepared as described (7) from a bacteriophage with an ECP-encoding human genomic DNA insert;2 the transcriptional start site of the ECP gene was determined to be at the analogous site to the start site in the gene encoding EDN.3


Fig. 2. A, EMSA: nuclear proteins isolated from the human promyelocytic HL-60 cell line incubated with a radiolabeled double-stranded oligonucleotide probe d (see Fig. 1A). Lane 1, radiolabeled probe alone; lane 2, radiolabeled probe incubated with 0.22 µg/µl nuclear proteins; lane 3, nuclear proteins preincubated with a 100-fold excess of unlabeled probe prior to addition of radiolabeled probe; lane 4, nuclear proteins preincubated with a 100-fold excess of a nonspecific unlabeled 34-base pair double-stranded oligonucleotide prior to addition of radiolabeled probe; lane 5, nuclear proteins preincubated with a 100-fold excess of an unlabeled double-stranded oligonucleotide specifying the NFAT-1 sequence (see Fig. 1A) prior to addition of radiolabeled probe. Arrow indicates the mobility of the unbound probe. B, supershift analysis: lane 1, radiolabeled probe alone; lane 2, radiolabeled probe incubated with 1 µl of a 1:1000 dilution of anti-NFAT-1 antiserum (10); lane 3, radiolabeled probe incubated with 0.22 µg/µl nuclear proteins; lane 4, radiolabeled probe incubated with 0.22 µg/µl nuclear proteins and anti-NFAT-1 antiserum; lane 5, radiolabeled murine interleukin-2 promoter probe (10) incubated with 0.22 µg/µl nuclear proteins from Jurkat cells; lane 6, as in lane 5, with the addition of 1 µl of a 1:1000 dilution of anti-NFAT-1 antiserum. Lower arrow (probe) indicates the mobility of the unbound radiolabeled probes; upper arrow (a) denotes the supershift complex in lane 6.
[View Larger Version of this Image (41K GIF file)]


Sequence Mutations

The NFAT-1 consensus sequence (nucleotides 126-131) found in the promoter of EDN was altered by overlapping mutagenesis (29) of EDN3-CAT, creating EDN3M-CAT (see Fig. 3A) using the following oligonucleotide primer pairs: A and D, and B and C. Primer A: 5'-CTG CAG GCA GCA TAT AGT TTT CAT-3', nucleotides -312 to -288; primer B, 5'-CTG TAA GAA AAG AAG AGA AGT AAC-3', nucleotides 172-149; primer C: 5'-GGG GCA GCA ACT GAG TTC TCC GAG AGC TGA CGT TAG, nucleotides 111-146; and primer D: 5'-CTA ACG TCA GCT CTC GGA GAA CTC AGT TGC TGC CCC, nucleotides 146-111.


Fig. 3. A, schematic of the genomic structure of the EDN and ECP genes. Areas of sequence denoted by the filled bars below were introduced 5' to the CAT reporter gene. EDN3M, complete substitution of nucleotides making up the NFAT-1 consensus binding site, 5'-GGAGAA-3', with residues 5'-TTCTCC-3'; ECP3A, substitution of the nucleotide G at the 3' end of the NFAT-1 sequence in the ECP gene with the nucleotide A from the analogous site in EDN. B, relative CAT activity of the EDN and ECP reporter gene constructs described in A transfected into cells of the K-562, HL-60, and clone 15 human hematopoietic cell lines. The lanes marked CAT represent the relative activity of the promoterless reporter gene construct, pCAT-basic. C, relative CAT activity of the ECP reporter gene constructs described in A transfected into cell lines described in B.
[View Larger Version of this Image (17K GIF file)]


The NFAT-1 consensus sequence found in the promoter of EDN was introduced into the homologous site in the ECP promoter (nucleotides 126-131) also by overlapping mutagenesis (29) of ECP3-CAT, creating ECP3A-CAT using the following oligonucleotide primers (E and F) paired with primers A and D, respectively, as described above. Primer E: 5'-AGG GCA GCA CCT GAG GGA GAA GTG AGC TGA AGT TAG, nucleotides 111-146; and primer F: 5'-CTA ACT TCA GCT CAC TTC TCC CTC AGG TGC TGC CCT, nucleotides 146-111.

CAT Analysis

Cells from the human cell lines indicated were grown to a density of 0.5 1 × 106 to 1 × 106 cells/ml, harvested by centrifugation, washed, and resuspended at 30 × 106 cells/ml in growth medium as described above. Ten µg of uncut reporter gene construct along with 10 µg of uncut pCMV (cytomeglovirus)-beta -galactosidase plasmid (Promega) were added to a 0.5-ml cell suspension in an electroporation cuvette (0.4-cm gap) (Bio-Rad). Electroporation, harvest, CAT and beta -galactosidase assays were as described previously (7).

Isolation of Nuclear Proteins

Nuclear protein fractions were obtained from cells of the HL-60 human promyelocytic leukemia cell line for use in electrophoretic mobility shift assays as described below. Cells (1 × 108 in log phase growth) were harvested (2000 rpm for 5 min) and washed once in sterile, ice-cold phosphate-buffered saline without calcium or magnesium. The washed cells were resuspended in 1.25 ml of cold buffer containing 10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol, 0.3 M sucrose, 0.1 mM EGTA, 0.5 mM phenylmethylsulfonyl fluoride (Sigma), and protease inhibitors (Boehringer Mannheim) as follows: 50 µg/ml antipain dihydrochloride, 0.7 µg/ml pepstatin, 330 pg/ml phosphoramidon, 2 µg/ml aprotinin, 60 µg/ml chymostatin, 0.5 µg/ml leupeptin, 40 µg/ml bestatin, 10 µg/ml E-64, and 1 mg/ml Pefabloc. Resuspended cells were harvested and resuspended in 0.5 ml of the same buffer and lysed in with 15 strokes with a B type pestle in a Dounce homogenizer. The supernatant containing the cytosolic contents from the lysed cells was removed, and the pelleted nuclei were resuspended in 0.3 ml of ice-cold buffer as described above, with the addition of 25% glycerol and 0.2 mM EDTA. The resuspended nuclei were shaken (gentle agitation) for 30 min at 4 °C, and the resulting supernatant, harvested after centrifugation (12,000 rpm for 15 min at 4 °C), was dialyzed in a 10-kDa pore size membrane (Spectrum Laboratories, Houston, TX) at 4 °C against more than 100 volumes of buffer containing 20 mM HEPES, pH 7.9, 20% glycerol, 10 mM KCl, 0.5 mM dithiothreitol, 0.2 mM EDTA, and 0.5 mM phenylmethylsulfonyl fluoride for 3-5 h. The dialyzed supernatant was clarified by centrifugation, and protein concentration was measured using the BCA protein assay reagent system (Pierce). Nuclear extracts were aliquoted and stored at -80 °C.

Electrophoretic Mobility Shift Assay (EMSA)

Complementary oligonucleotides E and F as described above were hybridized by heating to 65 °C, followed by gradual cooling (15 min) to 37 °C. The 5' ends of each strand were phosphorylated with 50 µCi [gamma -32P]ATP (6000 Ci/mmol; DuPont NEN) and T4 polynucleotide kinase (Boehringer Mannheim) purified by phenol-chloroform extraction and redissolved in 10 mM Tris, pH 7.5, with 1 mM EDTA. One µl of the radiolabeled oligonucleotide probe was added to 17 µl of gel shift incubation buffer (Stratagene, La Jolla, CA) and 5 µl of a 1 µg/µl preparation of nuclear proteins described above (or distilled H2O as a negative control). Competing unlabeled oligonucleotide was added in 100-fold excess prior to the addition of the labeled probe. After a 30-min incubation at room temperature, 2 µl of 0.1% bromphenol blue dye was added, and 5 µl of each sample were evaluated by electrophoresis in a 6% polyacrylamide DNA retardation gel prepared with 0.5 × Tris-borate-EDTA (TBE) (Novex, San Diego, CA) with 0.25 × TBE running buffer at a constant 100V, 6-15 mA at room temperature.

Supershift analysis was performed using a polyclonal anti-NFAT-1 antiserum described by McCaffrey et al. (Ref. 10; Upstate Biotechnology, Inc., Lake Placid, NY). EMSA was performed as described above; 1 µl of a 1:1000 dilution of the NFAT-1 antibody was added 10 min after addition of the probe to the nuclear extract and then allowed to incubate an additional 30 min. Positive control included the NFAT-1 recognition sequence described in Ref. 10 incubated with the same dilution of antiserum and nuclear extract from Jurkat (human T lymphoma) cells, also as described (10).


RESULTS

Reporter Gene Activity/ECP

Shown in Fig. 1A is a comparison of the genomic sequences of EDN and ECP; exons 1 and 2 are demarcated by brackets. Also indicated are the sequences of probes and consensus sites that are described in the text. Fig. 1B diagrams the regions of ECP gene used to create the reporter gene constructs. Segments including the 5' promoter region (ECP1), promoter with exon 1 (ECP2) and promoter with exon 1 and intron (ECP3) were inserted 5' to the CAT reporter gene. Various human hematopoietic cell lines were transfected with these constructs, and the ability of each to support reporter gene activity was measured. As shown in Fig. 1C, the ECP promoter (ECP1-CAT) and promoter with noncoding exon 1 (ECP2-CAT) supported only slightly more reporter gene activity than that supported by (promoterless) CAT alone in the HL-60 promyelocytic leukemia cell line (1.2-fold and 1.1-fold, respectively). Addition of the intron (ECP3-CAT) led to a 9-fold increase in reporter gene activity. Similar results were obtained in two additional cell lines tested; whereas ECP1-CAT or ECP2-CAT supported relatively small increases in activity, the activity of ECP3-CAT was measured at 8-fold and 18-fold over CAT in the HL-60 clone 15 and K-562 cell lines, respectively. These results suggest that optimal expression of the ECP gene depends on a sequence element (or elements) present in the single intron, analogous to, albeit less dramatic than, the results obtained previously for the gene encoding EDN (Ref. 7; Fig. 1C).


Fig. 1.

A, sequence comparison of EDN and ECP genes. Features indicated include consensus CAAT and TATA box sequences within the 5' promoters (overlined sections a and b, respectively), exons 1 and 2, and the single intron. Consensus transcription factor binding sites (AP-1, NFAT-1, and PU.1) are overlined and labeled. Probes used in the EMSA (Fig. 2) are shown as overlined sections c and d. B, schematic of the genomic structure of the ECP gene. Areas of ECP sequence denoted by the filled bars below were introduced 5' to the CAT reporter gene; ECP1, 5' promoter region; ECP2, 5' promoter region with exon 1; ECP3, 5' promoter region with exon 1 and intron. C, relative CAT activity of the ECP reporter gene constructs described in B transfected into cells of the HL-60, clone 15, and K-562 human hematopoietic cell lines. The EDN3-CAT construct contains the promoter/exon 1/intron of the EDN gene, as described in Ref. 7. The lane marked CAT indicates the relative activity of the promoterless reporter gene construct, pCAT-basic. The analysis of variance test indicates significant differences between the values obtained for ECP3-CAT and those obtained for EDN3-CAT in all three cell lines at p < 0.05 (n = 2 for HL-60 and clone 15; n = 3 for K-562).


[View Larger Version of this Image (29K GIF file)]


EMSA/NFAT-1 Consensus Binding Sequence within the Intron of the EDN Gene

We have shown previously that a significant portion of the intron-mediated enhancer activity of EDN resides in the first 60 base pairs (nucleotides 68-133) of the intron (7). In order to assess the presence of specific binding sites, EMSA or gel shift analysis was performed with nuclear proteins isolated from the promyelocytic leukemia HL-60 cells. Nuclear proteins were incubated with radiolabeled double-stranded oligonucleotide probes c and d corresponding to nucleotides 68-103 and 104-137, respectively (Fig. 1A). As shown in Fig. 2A, two distinct bands migrating more slowly than the unbound probe (probe d) were detected after incubation with the HL-60 nuclear proteins. These bands could not be detected in incubations that included a 100-fold excess of unlabeled probe, suggesting recognition of a specific sequence element or elements by one or more nuclear proteins in this extract. Additionally, these bands could not be detected in incubations that included a double-stranded oligonucleotide that encoded the NFAT-1 consensus site (nucleotides 126-131). No competition was seen in the presence of a random 34-base pair double-stranded oligonucleotide or from oligonucleotide probes corresponding to any of the other sequences within the original probe (data not shown), suggesting the presence of a specific nuclear protein or proteins binding to the NFAT-1 consensus site (nucleotides 126-131). No specific binding was observed in gel shift experiments in which nuclear protein fractions were incubated with the double-stranded oligonucleotide probe c (nucleotides 68-103; data not shown).

In order to determine whether the protein binding to the consensus site could be identified as immunoreactive NFAT-1, supershift analysis was performed using a polyclonal antiserum raised against purified NFAT-1 protein (10). Although a supershift was observed using the anti-NFAT-1 antiserum in conjunction with the consensus site probe and nuclear extract described by McCaffrey et al. (10), no supershift was observed using the anti-NFAT-1 antiserum with the HL-60 nuclear proteins and probe d (Fig. 2B), suggesting the possibility that another protein, perhaps another member of the NFAT family of transcription factors, binds specifically to this intron-based consensus sequence.

Reporter Gene Activity/Mutagenesis of the EDN and ECP Intronic NFAT-1 Consensus Sequences

In order to determine the functional significance of this consensus site, each nucleotide was altered (5'-GGAGAA-3' to 5'-TTCTCC-3'), creating EDN3M-CAT (Fig. 3A). The HL-60, K562, and clone 15 cell lines were transfected with this construct, and the reporter gene activity was compared directly to that supported by EDN3-CAT and CAT alone. We have previously shown that EDN3-CAT supported reporter gene activity 20-30-fold over that of the promoterless CAT construct (Ref. 7; Fig. 1C). As shown in Fig. 3B, the reporter gene activity of EDN3M-CAT was reduced to that observed for promoterless CAT alone in both the HL-60 and K562 cells. In the clone 15 cell line, disruption of the NFAT-1 site did not totally abolish reporter gene activity but reduced it to 50% of that observed for the EDN3-CAT construct with the consensus site intact.

Interestingly, the NFAT-1 consensus site in the analogous site in the ECP gene differs by a single nucleotide, with a G, rather than an A, at the 3' end (see Fig. 1A). To evaluate the role played by this single base pair change in this apparently crucial site, a 3' G to A conversion was introduced into the consensus site encoded by the ECP intron, creating ECP3A-CAT (Fig. 3A). The HL-60, K562, and clone 15 cell lines were transfected with this construct, and the reporter gene activity was compared directly to that supported by ECP3-CAT and CAT alone. We have previously shown that ECP3-CAT supported reporter gene activity 9-fold over that of the promoterless CAT (Fig. 1C); as shown in Fig. 3C, the reporter gene activity of the altered construct was significantly greater than that of ECP3-CAT, from 15- and 17-fold over CAT in the HL-60 and K562 cell lines, respectively, to 28-fold over CAT in clone 15, similar to the levels of enhancement observed for EDN3-CAT in this cell line.


DISCUSSION

In our previous work we showed that that the presence of the single intron was necessary for optimal expression of the gene encoding the eosinophil ribonuclease EDN (7). In this work, we have shown that the gene encoding the eosinophil ribonuclease ECP is regulated in an analogous fashion and that a consensus binding sequence for the transcription factor NFAT-1 (8-11) found in the introns of both EDN and ECP genes play a crucial role in enhancing their expression. Although originally described as specific to T lymphocytes, NFAT-1 has been found to participate in transcriptional regulation in mast cells, endothelial cells, and B lymphocytes (12, 24-27). This work suggests the possibility of a role for NFAT-1 and/or related proteins (30, 31) in the transcriptional control of genes expressed in human granulocytes. Interestingly, whereas the NFAT-1 sequence accounts for the entire intron-mediated enhancer activity found in both the promyelocytic HL-60 cells and the chronic myelogenous leukemia K-562 cells, this is not the case in the eosinophilic variant of HL-60, clone 15; in the clone 15 cells, elimination of the NFAT-1 consensus in the EDN intron (EDN3M-CAT) reduced the intron-mediated enhancer activity by only 50%. Similarly, the reporter gene activity of the ECP3A-CAT construct, with the 3' G to A conversion of the consensus site in the ECP intron, showed the most dramatic enhancement in the clone 15 cells. The results obtained with the EDN3M-CAT construct suggest the presence of yet another (perhaps eosinophil-specific) active intronic enhancer element participating in the promoter/intron interaction in the clone 15 cell line; the results obtained with the ECP3A-CAT construct suggest a cooperative interaction between this putative site and the 3' A version of the NFAT-1 consensus sequence.

The NFAT-1 consensus sequence situated in the EDN intron, 5'-GGAGAA-3', can also be found in the regulatory regions of genes encoding other granulocyte proteins, including eosinophil peroxidase (32), lactoferrin (33), Charcot-Leyden crystal protein (34), and major basic protein (35); this consensus sequence may have a wider role in the regulation of gene expression in the granulocyte lineages than has been previously appreciated. Particularly interesting is the potential relationship between this consensus sequence and the rare genetic disease, neutrophil-specific granule deficiency, which is a disorder of transcription of granule proteins affecting both the neutrophilic and eosinophilic granulocyte lineages (36, 37). Although NFAT-1 is expressed in a variety of tissues, the results of the supershift analysis suggest a different identity for this protein; it remains to be seen whether this consensus sequence binding protein is a variant of NFAT-1, a member of the NFAT family of transcription factors (34, 35), or something completely unique. Future studies will seek to identify this protein, to determine its role in the regulation of EDN and ECP gene expression, and to assess its involvement in the physiology and pathophysiology of the human granulocyte lineages.


FOOTNOTES

*   The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    To whom correspondence should be addressed: Building 10, Room 11N104, LHD/NIAID/NIH, 9000 Rockville Pike, Bethesda, MD 20892. Tel.: 301-402-9131; Fax: 301-402-4369; E-mail: hr2k{at}nih.gov.
1    The abbreviations used are: EDN, eosinophil-derived neurotoxin; ECP, eosinophil cationic protein; CAT, chloramphenicol acetyltransferase.
2    K. D. Dyer, and H. F. Rosenberg, unpublished data.
3    H. L. Tiffany, and H. F. Rosenberg, unpublished data.

REFERENCES

  1. Spry, C. J. F. (1988) Eosinophils: A Comprehensive Review and Guide to the Scientific and Medical Literature, Oxford University Press, Oxford
  2. Ackerman, S. J. (1993) in Eosinophils: Biological and Clinical Aspects (Makino, S., and Fukuda, T., eds), pp. 33-74, CRC Press, Boca Raton, FL
  3. Samuelson, L. C., Wiebauer, K., Howard, G., Schmid, R. M., Koeplin, D., and Meisler, M. H. (1991) Nucleic Acids Res. 19, 6935-6941 [Medline] [Order article via Infotrieve]
  4. Hamann, K. J., Ten, R. M., Loegering, D. A., Jenkins, R. B., Hiese, M. T., Schad, C. R., Pease, L. R., Gleich, G. J., and Barker, R. L. (1990) Genomics 7, 535-546 [Medline] [Order article via Infotrieve]
  5. Kurachi, K., Davie, E. W., Strydom, D. J., Riordan, J. F., and Vallee, B. L. (1985) Biochem. 24, 5494-5499 [Medline] [Order article via Infotrieve]
  6. Carsana, A., Confalone, E., Palmieri, M., Libonati, M., and Furoa, A. (1988) Nucleic Acids Res. 1, 5491-5502
  7. Tiffany, H. L., Handen, J. S., and Rosenberg, H. F. (1996) J. Biol. Chem. 271, 12387-12393 [Abstract/Free Full Text]
  8. Ullman, K. S., Northrop, J. P., Verweij, C. L., and Crabtree, G. R. (1990) Annu. Rev. Immunol. 8, 421-452 [CrossRef][Medline] [Order article via Infotrieve]
  9. Flanagan, W. M., Corthesy, B., Bram, R. J., and Crabtree, G. R. (1990) Nature 352, 803-807
  10. McCaffrey, P. G., Luo, C., Kerpola, T. K., Jain, J., Badalian, T. M., Ho, A. M., Burgeon, E., Lane, W. S., Lambert, J. N., Curran, T., Verdine, G. L., Rao, A., and Hogan, P. G. (1993) Science 262, 750-754 [Medline] [Order article via Infotrieve]
  11. McCaffrey, P. G., Perrino, B. A., Soderling, T. R., and Rao, A. (1993) J. Biol. Chem. 268, 3747-3752 [Abstract/Free Full Text]
  12. Cockerill, P. N., Shannon, M. F., Bert, A. G., Ryan, G. R., and Vadas, M. A. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2466-2740 [Abstract]
  13. Chuvpilo, S., Schomberg, C., Gerwig, R., Heinfling, A., Reeves, R., Grummt, F., and Serfling, E. (1993) Nucleic Acids Res. 21, 5694-5704 [Abstract]
  14. Szabo, S. J., Gold, J. S., Murphy, T. L., and Murphy, K. M. (1993) Mol. Cell Biol. 13, 4793-4805 [Abstract]
  15. Rooney, J. W., Hodge, M. R., McCaffrey, P. G., Rao, A., and Glimcher, L. H. (1994) EMBO J. 13, 625-633 [Abstract]
  16. 63976405Hodge, M. R., Rooney, J. W., and Glimcher, L. H. (1995) J. Immunol. 6397-6405
  17. Lee, H. J., Masuda, E. S., Arai, N., Arai, K., and Yokota, T. (1995) J. Biol. Chem. 270, 17541-17550 [Abstract/Free Full Text]
  18. Schubert, L. A., King, G., Cron, R. Q., Lewis, D. B., Aruffo, A., and Hollenbaugh, D. (1995) J. Biol. Chem. 270, 29624-29627 [Abstract/Free Full Text]
  19. Masuda, E. S., Tokumitsu, H., Tsuboi, A., Shlomai, J., Hunt, P., Arai, K., and Arai, N. (1993) Mol. Cell Biol. 13, 7399-7407 [Abstract]
  20. 12401251Jenkins, F., Cockerill, P. N., Bohmann, D., and Shannon, M. F. (1995) J. Immunol. 1240-1251
  21. Goldfeld, A. E., McCaffrey, P. G., Strominger, J. L., and Rao, A. (1993) J. Exp. Med. 178, 1365-1379 [Abstract]
  22. Jain, J., McCaffrey, P. G., Vlage-Archer, V. E., and Rao, A. (1992) Nature 356, 801-804 [CrossRef][Medline] [Order article via Infotrieve]
  23. Ruff, V. A., and Leach, K. L. (1995) J. Biol. Chem. 270, 22602-22607 [Abstract/Free Full Text]
  24. Brabletz, T., Pietrowski, I., and Serfling, E. (1991) Nucleic Acids Res. 19, 61-67 [Abstract]
  25. Choi, M. S. K., Brines, R. D., Holman, M. J., and Klaus, G. G. B. (1994) Immunity 1, 179-187 [Medline] [Order article via Infotrieve]
  26. Venkatataraman, L., Francis, D. A., Wang, Z., Liu, J., Rothstein, T. L., and Sen, R. (1994) Immunity 1, 89-96
  27. Prieschl, E. E., Pendl, G. G., Harrer, N. E., and Baumruker, T. (1996) J. Immunol. 155, 4963-4970 [Abstract]
  28. Ho, A. M., Jain, J., Rao, A., and Hogan, P. G. (1994) J. Biol. Chem. 269, 28181-28186 [Abstract/Free Full Text]
  29. Higuchi, R. (1990) in PCR Protocols (Innis, M. A., Gelfand, D. H., Sninsky, J. J., and White, T. J., eds), pp. 177-183, Academic Press, San Diego, CA
  30. Hoey, T., Sun, Y., Williamson, K., and Xu, X. (1995) Immunity 2, 461-472 [Medline] [Order article via Infotrieve]
  31. Northrop, J. P., Ho, S. N., Chen, L., Thomas, D. J., Timmerman, A., Nolan, G. P., Admon, A., and Crabtree, G. R. (1994) Nature 369, 497-501 [CrossRef][Medline] [Order article via Infotrieve]
  32. Ten, R. M., Pease, L. R., McKean, D. J., Bell, M. P., and Gleich, G. J. (1989) J. Exp. Med. 169, 1757-1769 [Abstract]
  33. Johnston, J. J., Rintels, P., Chung, J., Sather, J., Benz, E. J., Jr., and Berliner, N. (1992) Blood 79, 2998-3006 [Abstract]
  34. Ackerman, S. J., Corrette, S. E., Rosenberg, H. F., Bennett, J. C., Mastrianni, D. M., Nicholson-Weller, A., Weller, P. F., Chin, D. T., and Tenen, D. G. (1993) J. Immunol. 150, 456-468 [Abstract/Free Full Text]
  35. Barker, R. L., Loegering, D. A., Arakawa, K. C., Pease, L. R., and Gleich, G. J. (1990) Gene 86, 285-289 [CrossRef][Medline] [Order article via Infotrieve]
  36. Lomax, K. J., Gallin, J. I., Rotrosen, D., Raphael, G. D., Kaliner, M. A., Benz, E. J., Boxer, L. A., and Malech, H. L. (1989) J. Clin. Invest. 83, 514-519 [Medline] [Order article via Infotrieve]
  37. Rosenberg, H. F., and Gallin, J. I. (1993) Blood 82, 268-273 [Abstract]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.